CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience | Invitrogen 14-1347-82 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience

catalog :

14-1347-82

quantity :

100 µg

price :

US 135.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

ACT35 (ACT-35)

reactivity :

human

application :

immunohistochemistry, flow cytometry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section

more info or order :

Invitrogen product webpage

citations: 12

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human; loading ...	Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed publisher
	Theodoraki M, Laban S, Jackson E, Lotfi R, Schuler P, Brunner C, et al. Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients. Br J Cancer. 2021;125:1677-1686 pubmed publisher
	Autio M, Leivonen S, Brück O, Mustjoki S, Mészáros Jørgensen J, Karjalainen Lindsberg M, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2021;106:718-729 pubmed publisher
	Reuben A, Spencer C, Prieto P, Gopalakrishnan V, Reddy S, Miller J, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017;2: pubmed publisher
	Cooper Z, Reuben A, Spencer C, Prieto P, Austin Breneman J, Jiang H, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016;5:e1136044 pubmed
	Voo K, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer. 2014;135:2834-46 pubmed publisher
	Turcotte S, Gros A, Hogan K, Tran E, Hinrichs C, Wunderlich J, et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol. 2013;191:2217-25 pubmed publisher
	Kshirsagar S, Binder E, Riedl M, Wechselberger G, Steichen E, Edelbauer M. Enhanced activity of Akt in Teff cells from children with lupus nephritis is associated with reduced induction of tumor necrosis factor receptor-associated factor 6 and increased OX40 expression. Arthritis Rheum. 2013;65:2996-3006 pubmed publisher
	Heninger A, Theil A, Wilhelm C, Petzold C, Huebel N, Kretschmer K, et al. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J Immunol. 2012;189:5649-58 pubmed publisher
	Pratico E, Sullenger B, Nair S. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther. 2013;23:35-43 pubmed publisher
	Triplett T, Curti B, Bonafede P, Miller W, Walker E, Weinberg A. Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol. 2012;42:1893-905 pubmed publisher
	Kashiwakura J, Ando T, Matsumoto K, Kimura M, Kitaura J, Matho M, et al. Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy. J Clin Invest. 2012;122:218-28 pubmed publisher

product information

Product Type :

Antibody

Product Name :

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience

Catalog # :

14-1347-82

Quantity :

100 µg

Price :

US 135.00

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent

Species :

Human

Clone :

ACT35 (ACT-35)

Isotype :

IgG1, kappa

Storage :

4° C

Description :

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent

Aliases :

ACT35; ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; IMD16; Ly-70; lymphoid activation antigene ACT35; MRC OX40; Ox40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 receptor; TNF receptor superfamily member 4; Tnfrsf4; tumor necrosis factor (ligand) superfamily member 4; tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4; tumor necrosis factor superfamily, member 4; Txgp1; Txgp1l

more info or order :

Invitrogen product webpage